P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.975
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.16-03 Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Efficacy and Potential Predictive Factors of PD-1/PD-L1 Blockades in Epithelial Carcinoma Patients: A Systematic Review and Meta Analysis

Oncotarget
Oncology
2016English

The Efficacy and Safety of Combination of PD-1 and CTLA-4 Inhibitors: A Meta-Analysis

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2019English

The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Erratum: The Efficacy and Safety of Anti‐PD‐1/Pd‐l1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First‐line Treatment for Advanced Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

Comprehensive Analysis of PD-L1 Expression in Glioblastoma Multiforme

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy